I wish there was news. I've been wishing for news ever since we filed our topline data from the LIVE-AIR trial in March of 2021, just one year after covid hit our shores. That was an incredible achievement, especially for a small-cap biotech. Lenz could have saved the lives of many who were lost; it could have improved the quality of life in patients that couldn't be saved; and it could also have improved the quality of life of those of us who invested here. I think management is steadfast in their effort to achieve success, and I owe them support in their quest.